Amgen dismisses bone density concerns related to its weight-loss …
1 day ago · Nov 13 (Reuters) - Amgen (AMGN.O) said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 ...
Amgen Defends Its Investigational Monthly Weight Loss Injection …
1 day ago · On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. On Wednesday, Amgen Inc ...
Amgen Puts Its Weight Behind Obesity Drug With Potential ... - MedCity News
Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds. Amgen is confident its injectable obesity drug would have a differentiated profile compared to...
Amgen Says No Link Between MariTide, Bone Density Loss
1 day ago · Resize. By Colin Kellaher. Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more ...
Amgen axes an obesity asset, zooms in on MariTide - Fierce Biotech
May 2, 2024 · Amgen axes obesity asset after phase 1 results, zooms in on MariTide. Amgen is axing obesity candidate AMG 786 and going all in on later-stage asset MariTide. “Given the profile we've...
Amgen's potential Ozempic competitor sends stock up 13
May 3, 2024 · Amgen's potential weight loss drug is heading to a larger phase 3 trial. By. Bruce Gil. Published May 3, 2024. Topline results of Amgen’s phase 2 trial of its experimental weight loss drug,...
Amgen Sees No Bone Safety Concerns Around Experimental ... - U.S. News
1 day ago · An Amgen sign is seen at the company's headquarters in Thousand Oaks, California, U.S., November 6, 2019. REUTERS/Deena Beasley/File Photo. (Reuters) - Amgen said on Wednesday it does not see any ...
Amgen's Novel Weight Loss Drug Shows Potential for Longer …
Feb 6, 2024 · Amgen’s novel weight loss drug candidate maridebart cafraglutide (MariTide) showed significant promise in a Phase I trial (NCT04478708), with data suggesting longer lasting and durable reductions in body weight compared with the popular glucagon-like peptide (GLP)-1 agonists currently on the market—Novo Nordisk’s Wegovy (semaglutide) and ...
Amgen obesity drug MariTide: four key questions going forward
May 3, 2024 · Mark J. Terrill/AP. A mgen’s comments Thursday that it’s “very encouraged” by interim Phase 2 data for its obesity drug have quickly sparked immense investor interest in what could be a potential...
AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT …
Dec 1, 2022 · Amgen moved into this Phase 1 study based on human genetic insights and preclinical evidence that suggested synergistic effects with GIP receptor blockade and GLP-1 receptor agonism on weight loss and improvement in other metabolic parameters.